University of Vermont

College of Medicine

Vermont Cancer Center

trials_lung

Lung Cancer Clinical Trials

The Vermont Cancer Center has many trials specifically focused on lung cancer research.

Status: Active - Recruiting
Study Title: A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<2 cm) Peripheral Non-Small Cell Lung Cancer
Purpose: This randomized phase III trial is studying different types of surgery to compare how well they work in treating patients with stage IA non-small cell lung cancer.
ClinicalTrials.gov Identifier: NCT00499330
Primary/Site/Co Investigator: Bruce J Leavitt, MD
Contact: Elizabeth Eldridge (802) 656-2178
Information: http://www.clinicaltrials.gov/ct2/show/NCT00499330
Institution Number:95-106 CALGB 140503
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title: c-Jun N Terminal Kinase EMT and Lung Cancer
Purpose: The purpose of the study is to identify the role of c-Jun-N-terminal kinase-1 (JNK1) in epithelial to mesenchymal transition, and the role that JNK1 plays in this setting in the development of lung cancer. This study incorporates the use of human lung cancer specimens with KRas mutations, and JNK1 gene ablation studies in a K-Ras lung cancer model in the mouse.
ClinicalTrials.gov Identifier: N/A
Primary/Site/Co Investigator: Yvonne Janssen-Heininger, PhD
Contact: Yvonne Janssen-Heininger, PhD (802) 656-0995
Information: N/A
Institution Number: M11-210, VCC Lab 1100; Juckett Awardee
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title: A151216 – Genetic Testing for Patient with Resectable or Resected Lung Cancer
Purpose: The management of advanced lung cancer has been transformed based on tumor genetic testing. Tumor tissue is analyzed to identify genetic changes of epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangements.  EGFR and ALK are both proteins found on the surface of cells and these genetic changes indicate sensitivity to treatment with tyrosine kinase inhibitors such as erlotinib and crizotinib.  

This current study, A151216 (ALCHEMIST), lays the groundwork for applying genetic testing directed therapies to resected lung cancer to determine whether therapy with tyrosine kinase inhibitors can improve cure rates in earlier stage disease.   The ALCHEMIST trial will screen patients with resected non-small cell lung cancer for EGFR mutations and ALK rearrangements  in a centralized CLIA-certified laboratory using resources from the NCI to facilitate accrual to randomized adjuvant studies.   Centralized testing will also minimize technical inconsistencies, provide access to genetic testing and allow additional genetic testing to be performed over time to study other subtypes of the disease. 

Patients who participate in this study will undergo collection of blood and tissue samples for centralized genetic testing of EGFR and ALK.  Patients who have had surgery prior to pre-registration will submit samples from the previous surgery for testing.  Based on the result of this centralized testing, participation in a treatment trial may be offered.    There are two additional treatment studies randomizing this specific lung cancer population to treatment with targeted therapy:

A081105:  A Randomized Double-Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer;  or

E4512 A Double-Blind  Trial of Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinb versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein. 

If the tumor does not have either of these genetic changes present, standard of care treatment will be offered, however, the patient will be followed for 5 years as part of this study.

A secondary objective of this study is to characterize the natural history of EFGR and ALK wild-type lung cancers to allow subsequent development of targeted therapies in the adjuvant and recurrent settings.
ClinicalTrials.gov Identifier: NCT02194738
Primary/Site/Co Investigator: Claire Verschraegen, MD
Information: https://clinicaltrials.gov/ct2/show/NCT02201992?term=4512&rank=1
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title: Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Purpose: This is a 2 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin and paclitaxel versus the addition of placebo plus carboplatin and paclitaxel in subjects with advanced or metastatic squamous NSCLC.
ClinicalTrials.gov Identifier: NCT02106546
Contact: Hannah Eldred, BS, CRC (802) 656-9441
Information: http://www.clinicaltrials.gov/ct2/show/NCT02106546?term=abbvie+m11-089&rank=1
Institution Number: CHRMS 15-004
Protocol Research Type: Industry Sponsored
Status: Active - Closed to Accrual
Study Title: The CALGB Lung Cancer Tissue Bank
Purpose: The purpose of this study is to collect and store tissue and blood samples from patients with lung cancer to be tested in the laboratory.
ClinicalTrials.gov Identifier: NCT00899782
Primary/Site/Co Investigator: Bruce J Leavitt, MD
Contact: Elizabeth Eldridge (802) 656-2178
Information: http://www.clinicaltrials.gov/ct2/show/NCT00899782?term=CALGB+140202&rank=3
Institution Number: 95-106 CALGB 140202
Protocol Research Type: Cooperative Group
Status: Active - Closed to Accrual
Study Title: CALGB 31102 - Phase I Study of Accelerated Hypofractionated Radiation Therapy with Concomitant Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer
Purpose: For patients with locally-advanced non-small cell lung cancer (NSCLC) and a good performance status, the current “standard of care” is radiation with concurrent chemotherapy.  However, failure of radiotherapy to control gross disease is relatively common, suggesting that there is opportunity to improve radiotherapy techniques to optimize local control and potentially improve patient survival.  Increasing the total dose of radiotherapy with standard fractionation techniques has clearly reached a plateau, but technical advances in radiation therapy and cancer staging have led to an increased ability to target tumors while sparing normal tissue, making it possible to consider increases in the daily radiation dose as a possible avenue of advancement (accelerated hypofractionation).
ClinicalTrials.gov Identifier: NCT01486602
Primary/Site/Co Investigator: Ruth Heimann, MD
Contact: Elizabeth Eldridge (802) 656-2178
Information: N/A
Institution Number: M13-053
Protocol Research Type: Cooperative Group
Status: Active - Closed to Accrual
Study Title: A Multi-Center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination with Carboplatin and Etoposide (PaCE) Chemotherapy versus Carboplatin and Etoposide (CE) Alone in Chemotherapy Naïve Patients with Extensive-Stage Small Cell Lung Cancer.  The MATISSE Study. 
Purpose: The purpose of this study is to see if palifosfamide-tris with etoposide and carboplatin can extend the length of time that the disease is stable and extend life, compared to treatment with Etoposide and carboplatin alone. 
ClinicalTrials.gov Identifier: NCT01555710
Primary/Site/Co Investigator: Claire Verschraegen, MD
Contact: Kate Murray (802) 656-9401
Information: http://clinicaltrials.gov/ct2/show/NCT01555710?term=MATISSE&rank=2
Institution Number: M12-279
Protocol Research Type: Industry Sponsored

Last modified November 25 2014 04:29 PM